Mouse models of preterm birth: Suggested assessment and reporting guidelines

Ronald McCarthy
Washington University School of Medicine in St. Louis

Carmel Martin-Fairey
Washington University School of Medicine in St. Louis

Dorothy K. Sojka
Washington University School of Medicine in St. Louis

Erik D. Herzog
Washington University in St. Louis

Emily S. Jungheim
Washington University School of Medicine in St. Louis

See next page for additional authors

Follow this and additional works at: https://digitalcommons.wustl.edu/open_access_pubs

Recommended Citation
https://digitalcommons.wustl.edu/open_access_pubs/8823

This Open Access Publication is brought to you for free and open access by Digital Commons@Becker. It has been accepted for inclusion in Open Access Publications by an authorized administrator of Digital Commons@Becker. For more information, please contact vanam@wustl.edu.
Review

Mouse models of preterm birth: suggested assessment and reporting guidelines†

Ronald McCarthy1, Carmel Martin-Fairey1, Dorothy K. Sojka2, Erik D. Herzog3, Emily S. Jungheim4, Molly J. Stout4, Justin C. Fay5, Mala Mahendroo6, Jeff Reese7, Jennifer L. Herington7, Erin J. Plosa7, Elaine L. Shelton7 and Sarah K. England1,*

1Center for Reproductive Health Sciences, Department of Obstetrics and Gynecology, Washington University School of Medicine, St. Louis, Missouri, USA; 2Rheumatology Division, Washington University School of Medicine, St. Louis, Missouri, USA; 3Department of Biology, Washington University in St. Louis, St. Louis, Missouri, USA; 4Department of Obstetrics and Gynecology, Washington University School of Medicine, St. Louis, Missouri, USA; 5Department of Biology, University of Rochester, Rochester, New York, USA; 6Department of Obstetrics and Gynecology University of Texas Southwestern Medical Center, Dallas, Texas, USA and 7Department of Pediatrics, Vanderbilt University Medical Center, Nashville, Tennessee, USA

*Correspondence: Department of Obstetrics and Gynecology, Washington University in St. Louis School of Medicine, 425 South Euclid Avenue, Campus Box 8064, St. Louis, MO 63110. Tel: +(314) 286–1798; Fax: +(314) 747–4150; E-mail: englands@wustl.edu

†Grant support: This review was supported by NIH grants HD081121 (to JR), HD088830 (to JLH), and HL132805 (to ELS), and the March of Dimes Prematurity Research Center (to EDH, ESJ, JCF, MM, and SKE). SKE is supported by the Department of Obstetrics and Gynecology at Washington University and the March of Dimes Prematurity Research Center.

Received 26 January 2018; Revised 19 April 2018; Accepted 30 April 2018

Abstract

Preterm birth affects approximately 1 out of every 10 births in the United States, leading to high rates of mortality and long-term negative health consequences. To investigate the mechanisms leading to preterm birth so as to develop prevention strategies, researchers have developed numerous mouse models of preterm birth. However, the lack of standard definitions for preterm birth in mice limits our field's ability to compare models and make inferences about preterm birth in humans. In this review, we discuss numerous mouse preterm birth models, propose guidelines for experiments and reporting, and suggest markers that can be used to assess whether pups are premature or mature. We argue that adoption of these recommendations will enhance the utility of mice as models for preterm birth.

Summary Sentence

To improve reporting of mouse models of preterm birth, a set of universal guidelines and simple assays of developmental markers are proposed to distinguish between mature and premature pups.

Key words: preterm birth, mouse models, pregnancy, gestation, parturition.

Introduction

Every year, approximately 15 million babies (10% of all births worldwide) are born preterm, defined as delivery before 37 weeks of gestation [1–3]. Preterm birth is the leading cause of infant mortality [4], and those born prematurely have increased lifelong risks of adverse health outcomes including cognitive impairment, cardiovascular disease, and chronic pulmonary disease [5]. In approximately
one third of preterm births, labor is induced or cesarean section is performed because of maternal or fetal complications such as preeclampsia, intrauterine growth restriction, or fetal distress. However, the majority of preterm births are spontaneous, brought about by preterm labor (uterine contractions leading to cervical change and delivery) or preterm premature rupture of fetal membranes (PPROM) [6, 7]. Unfortunately, the multiple causes of preterm labor have not been fully determined, and we have limited ability to predict or prevent preterm birth [8–10].

To address these limitations, researchers have developed various mouse models of preterm birth [11]. Mice are useful for studying the timing of birth because they have a short gestation, can easily be genetically manipulated, are inexpensive, and can be studied in large numbers [12]. Additionally, key components of the labor and delivery process are conserved between mice and humans. For example, the expression levels of several proteins that activate uterine contractions including prostaglandins, oxytocin, and connexin-43 are elevated at term in both species [11, 13–15]. Finally, parturi-
tion timing is somewhat variable in both humans, in whom 90% of births occur between 37 and 42 weeks of gestation, and mice, in which gestation lengths vary between strains from 19 to 21 days [16].

Despite these similarities, three key physiological differences between human and mouse pregnancy are worth mentioning. First, whereas women typically have singleton pregnancies [17] within a single uterine cavity, mice commonly have 4 to 10 pups per litter (depending on strain) [16] within two uterine horns. This can complicate comparisons between species because women carrying multiple pregnancies are at increased risk for preterm birth [18]. Second, although progesterone is required to maintain pregnancy and is initially produced by the corpus luteum in both humans and mice, its production thereafter is regulated differently in the two species. In humans, the placenta takes over progesterone production after gestational week 7 or 8, and progesterone levels rise fairly continuously until the end of pregnancy [19, 20]. At the end of human pregnancy, a shift in progesterone receptor isoform expression and local increases in pro-
gesterone metabolism [21, 22] result in a functional withdrawal of the “pregnancy-maintaining” hormone. In mice, progesterone synthesis and levels decrease while local progesterone metabolism [23] increases dramatically in the last two days of pregnancy, facilitating the onset of parturition. Third, although estrogens inhibit uterine quiescence and promote cervical ripening after progesterone action decreases (by promoting production of uterotonins and contraction-associated proteins, including: connexin-43, oxytocin receptor, cyclo-oxygenase 2, and prostaglandin F receptor) in both humans and mice, estrogen is regulated differently in the two species. In humans, circulating estrogens, derived from the ovary and placenta, are high throughout gestation. In mice, estrogens are synthesized by the ovary at low levels in the first half of pregnancy and then markedly increase in the latter half of gestation.

As we detail in this review, “preterm birth” is loosely defined for mice, and our field lacks clear, accepted guidelines for conducting experiments and reporting results. Thus, we cannot easily compare mouse studies and use their results to improve our ability to predict and prevent preterm birth in women. This review seeks to fill this gap by describing mouse preterm birth models published in the literature and the ways in which they aim to represent the human condition. Additionally, we discuss experimental differences leading to inconsistent definitions of preterm birth in mice and propose criteria to provide more uniform assessment of mouse models. Finally, we suggest that investigators should assess and report the develop-
mental status (mature or premature) of offspring. Toward this end, we describe promising fetal developmental markers that can be used to distinguish between mature and premature pups.

### Mouse models of preterm birth

Here, we review the major classes of mouse preterm birth models, categorized by pathologic state. Representative examples are provided in Table 1.

### Infection

Multiple studies have implicated activation of inflammatory pathways in the process of normal uncomplicated labor (as reviewed in [24]). However, early initiation of the inflammatory pathway by infection contributes to between 25% and 40% of all human preterm births [25–27]. Infections can develop in two major ways. Chorioamnionitis or intrauterine infection can arise systemically, or commensal bacteria can ascend from the female genital tract. Several mouse models of infection-induced preterm birth have been developed [28, 29], most commonly using *Escherichia coli* or the toxic component on the surface of gram-negative bacteria, lipopolysaccha-
ride (LPS). Other bacteria associated with increased risk of preterm birth in humans, and therefore studied in mice, include *Ureaplasma, Chlamydia trachomatis*, Group B streptococcus (GBS; *Streptococcus agalactiae*), and *Porphyromonas gingivalis*. To mimic local in-
fec tion, investigators have performed intrauterine, intraamniotic, or intraperitoneal injections with live or heat-killed bacteria. To simu-
late systemic infection, they administer injections intraperitoneally, and to mimic ascending infections, they inject bacteria vaginally or via the intrauterine route [30–32].

Mice injected with live or heat-killed *E. coli* or LPS on 14.5–15.5 days post coitus (dpc) delivered within 7–48 h, depending on the route of administration and LPS serotype used. Specific *E. coli* derived LPS serotypes differentially activated proinflammatory re-
ponses, caused mice to deliver at different times postinjection, and were associated with varying levels of offspring survival [33]. Both *E. coli* and LPS stimulate the Toll-like receptor (TLR)-4 in the uterus and activate an inflammatory cascade [34]. Further investigation of localized intrauterine inflammation revealed that the TLR-4 pathway stimulated platelet activating factor, an important mediator of the signal transduction pathway that led to inflammatory-induced preterm delivery [35]. In addition, LPS administered vaginally has been shown to work through the complement receptor C5a, affecting cervical remodeling by increasing metalloproteinase-9 activity and collagen degradation [36].

Intrauterine injections of lipoteichoic acid (an anionic polymer on the surface of gram-positive bacteria), peptidoglycan (also a major component on the surface of gram-positive bacteria), or polyinosinic acid (an analog of viral double-stranded RNA) caused mice to deliver preterm by mechanisms similar to that of LPS, albeit through differ-
ent TLRs [37, 38]. Specifically, administration of the bacterial peptidoglycan-derived peptide γ-D-glutamyl-meso-diaminopimelic acid, an agonist of the pattern recognition receptor Nod-1, caused mouse preterm birth via maternal-fetal inflammation [39].

In humans, GBS is the leading cause of perinatal infection, and maternal GBS infection increases the risk for preterm birth [40, 41]. To model this etiology, Hirsch and colleagues injected pregnant mice (intraperitoneal or intrauterine) with 10⁵ heat-killed GBS on 14.5 dpc [42]. In this model, approximately 86% of pregnant mice delivered within 18 h and showed signs of placental and membrane

---

**Table 1.** Mouse models of infection-induced preterm birth

<table>
<thead>
<tr>
<th>Model Description</th>
<th>Route of Administration</th>
<th>LPS Serotype</th>
<th>Time to Delivery</th>
<th>Offspring Survival</th>
</tr>
</thead>
<tbody>
<tr>
<td><em>E. coli</em></td>
<td>Intraperitoneal, Intrauterine</td>
<td>15.5 dpc</td>
<td>7–48 h</td>
<td>Varies</td>
</tr>
<tr>
<td>LPS</td>
<td>Intraperitoneal, Intrauterine</td>
<td>14.5–15.5 dpc</td>
<td>7–48 h</td>
<td>Varies</td>
</tr>
<tr>
<td>Lipoteichoic acid</td>
<td>Intraperitoneal, Intrauterine</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Peptidoglycan</td>
<td>Intraperitoneal, Intrauterine</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Polyinosinic acid</td>
<td>Intraperitoneal, Intrauterine</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

---

*Note: dpc = days post coitus*
<table>
<thead>
<tr>
<th>Type of model</th>
<th>Targeted mutation</th>
<th>Mouse strain</th>
<th>Expected gestational length (days)</th>
<th>Breeding method</th>
<th>Defined start of pregnancy</th>
<th>Treatment/ experimental manipulation</th>
<th>Stimulant</th>
<th>Route and concentration</th>
<th>Day of injection</th>
<th>Preterm delivery definition</th>
<th>Term delivery definition in paper</th>
<th>Pup survival</th>
<th>Reference</th>
</tr>
</thead>
<tbody>
<tr>
<td>Infection</td>
<td>N/A</td>
<td>CD-1</td>
<td>19–20</td>
<td>ND</td>
<td>Vaginal plug; dpc not defined</td>
<td>E. coli 2 × 10^7 IU/IP</td>
<td>14.5 dpc</td>
<td>Within 48 h</td>
<td>ND</td>
<td>None</td>
<td>None</td>
<td>[31]</td>
<td></td>
</tr>
<tr>
<td></td>
<td>N/A</td>
<td>C3H/HeN x C3H/HeN</td>
<td>19–20</td>
<td>ND</td>
<td>Vaginal plug and spermatozoa in vaginal smear at 0.0 dpc</td>
<td>IP - 50 or 100 μg/kg (one injection) Or 50 μg/kg (two injections)</td>
<td>12, 15, or 17 dpc</td>
<td>&lt;19 dpc</td>
<td>19–20 dpc</td>
<td>None</td>
<td>None</td>
<td>[32]</td>
<td></td>
</tr>
<tr>
<td>N/A</td>
<td>CD-1</td>
<td>ND</td>
<td>ND</td>
<td>ND</td>
<td>Vaginal plug at 0.0 dpc</td>
<td>LPS serotypes 0111:B4, 055:B5, 0127:B8, and 0128:B12</td>
<td>IU 20 μg in 25 μl</td>
<td>16 dpc</td>
<td>36 h postinjection</td>
<td>60 ± 15 h postinjection</td>
<td>None</td>
<td>None</td>
<td>[33]</td>
</tr>
<tr>
<td>TLR-4 mutant</td>
<td>CD-1</td>
<td>C3H/HeJ</td>
<td>19–20</td>
<td>Timed pregnant (supplier)</td>
<td>ND</td>
<td>LPS serotype L2280 (CD-1) L2880 and L4525 for TLR-4 mutant No treatment, LPS serotype 055:B5 or RU486</td>
<td>IU 250 μg/mouse (Sigma)</td>
<td>15 dpc</td>
<td>At least 1 pup born &lt; 48 h after LPS admin</td>
<td>19–20 dpc</td>
<td>None</td>
<td>None</td>
<td>[35]</td>
</tr>
<tr>
<td>C5aR−/−</td>
<td>129S4/SvJae</td>
<td>ND</td>
<td>ND</td>
<td>Vaginal plug at 0 dpc</td>
<td>250 μg LPS intravaginally SC 150 μg RU486 dissolved in DMSO</td>
<td>15 dpc</td>
<td>Within 48 h postinjection</td>
<td>20–21 dpc</td>
<td>ND</td>
<td>None</td>
<td>[36]</td>
<td></td>
<td></td>
</tr>
<tr>
<td>N/A</td>
<td>CD-1</td>
<td>ND</td>
<td>ND</td>
<td>ND</td>
<td>Vaginal plug, dpc not defined</td>
<td>TLR-2 ligand lipoteichoic acid, peptidoglycan, or TLR-3 ligand polyinosinic:cytidylic acid</td>
<td>IU and IP</td>
<td>14.5 or 15.5 dpc</td>
<td>At least 1 pup born or in lower vagina &lt; 48 h after surgery</td>
<td>19–20 dpc</td>
<td>None</td>
<td>None</td>
<td>[37]</td>
</tr>
<tr>
<td>N/A</td>
<td>C3H/HeNCrj X Crj: B6D2F1</td>
<td>19–20</td>
<td>ND</td>
<td>Vaginal plug and spermatozoa in the vaginal smear at 0.0 dpc</td>
<td>Lipoteichoic acid IP 12.5–75 mg/kg single dose or repeated doses at 3h intervals</td>
<td>15 dpc</td>
<td>&lt;19.0 dpc</td>
<td>19–20 dpc</td>
<td>None with doses given on 15 dpc 100% viable with doses given on 17 dpc</td>
<td>None</td>
<td>[38]</td>
<td></td>
<td></td>
</tr>
<tr>
<td>N/A</td>
<td>C57BL/6</td>
<td>19.5 ± 0.5</td>
<td>ND</td>
<td>ND</td>
<td>iE-DAP</td>
<td>IP 500, 750, or 1000 μg in 200 μl PBS IP or IU 10^9 in 100 μl</td>
<td>14.5 dpc</td>
<td>Delivery within 24 h postinjection</td>
<td>ND</td>
<td>None</td>
<td>ND</td>
<td>[39]</td>
<td></td>
</tr>
<tr>
<td>N/A</td>
<td>CD-1</td>
<td>ND</td>
<td>Timed pregnant (supplier)</td>
<td>ND</td>
<td>Heat-killed GBS</td>
<td>Lipoteichoic acid IP 12.5–75 mg/kg single dose or repeated doses at 3h intervals</td>
<td>17 dpc</td>
<td>&lt;19.0 dpc</td>
<td>19–20 dpc</td>
<td>None with doses given on 15 dpc 100% viable with doses given on 17 dpc</td>
<td>None</td>
<td>[38]</td>
<td></td>
</tr>
<tr>
<td>Type of model</td>
<td>Targeted mutation</td>
<td>Mouse strain</td>
<td>Expected gestational length (days)</td>
<td>Breeding method</td>
<td>Defined start of pregnancy</td>
<td>Stimulant</td>
<td>Treatment/ experimental manipulation</td>
<td>Route* and concentration</td>
<td>Day of injection</td>
<td>Preterm delivery definition</td>
<td>Term delivery definition in paper</td>
<td>Pup survival</td>
<td>Reference</td>
</tr>
<tr>
<td>--------------</td>
<td>------------------</td>
<td>--------------</td>
<td>-----------------------------------</td>
<td>----------------</td>
<td>---------------------------</td>
<td>------------</td>
<td>-------------------------------------</td>
<td>------------------------</td>
<td>----------------</td>
<td>----------------------------</td>
<td>---------------------------------</td>
<td>-------------</td>
<td>-----------</td>
</tr>
<tr>
<td>N/A</td>
<td>C3H/HeN</td>
<td>19–20</td>
<td>ND</td>
<td>Vaginal plug at 0.0 dpc</td>
<td>Ureaplasma outer membrane lipoprotein</td>
<td>IU 15 μg</td>
<td>14.0 dpc</td>
<td>Within 48 h</td>
<td>ND</td>
<td>ND</td>
<td>[45]</td>
<td></td>
<td></td>
</tr>
<tr>
<td>N/A</td>
<td>BALB/c (H-2&lt;sup&gt;+&lt;/sup&gt;)</td>
<td>19–20</td>
<td>Overnight</td>
<td>Vaginal plug at 0 dpc</td>
<td>Chlamydia trachomatis mouse pneumonitis biovar (strain Nigg II)</td>
<td>10&lt;sup&gt;6&lt;/sup&gt; to 10&lt;sup&gt;7&lt;/sup&gt; inclusion-forming units in 20 μl of 0.2 M sucrose–20 mM sodium phosphate (pH 7.2)–5 mM glutamic acid</td>
<td>5 dpc</td>
<td>ND</td>
<td>19.3</td>
<td>Maternal cannibalism precluded evaluation</td>
<td>[47]</td>
<td></td>
<td></td>
</tr>
<tr>
<td>N/A</td>
<td>C3H/HeJ</td>
<td>20</td>
<td>Timed-pregnant (supplier)</td>
<td>ND</td>
<td>E. coli Dr&lt;sup&gt;+&lt;/sup&gt; IH11128 and Dr14</td>
<td>7 dpc</td>
<td>On or before 18 dpc</td>
<td>ND</td>
<td>53.6%</td>
<td>[50]</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>N/A</td>
<td>C57BL/6J</td>
<td>20.45</td>
<td>ND</td>
<td>Vaginal plug at 0.0 dpc</td>
<td>W83 strain of P. gingivalis</td>
<td>10&lt;sup&gt;5&lt;/sup&gt; CFU</td>
<td>6 weeks before mating</td>
<td>16.0 dpc</td>
<td>Delivery</td>
<td>ND</td>
<td>[55]</td>
<td></td>
<td></td>
</tr>
<tr>
<td>N/A</td>
<td>Faah&lt;sup&gt;−/−&lt;/sup&gt;; Cnr&lt;sup&gt;−/−&lt;/sup&gt;</td>
<td>~19.8</td>
<td>ND</td>
<td>Vaginal plug at 1.0 dpc</td>
<td>LPS serotype 0111:B4</td>
<td>IP 25 μg</td>
<td>15.5 dpc</td>
<td>15.5–17 dpc</td>
<td>18.0–20.0 dpc</td>
<td>~19.8 dpc</td>
<td>None</td>
<td>[139]</td>
<td></td>
</tr>
<tr>
<td>N/A</td>
<td>Kunming (derived from Swiss Webster)</td>
<td>ND</td>
<td>Overnight</td>
<td>Vaginal plug at 0.0 dpc</td>
<td>LPS serotype 0111</td>
<td>IP 10 μg</td>
<td>16.0 dpc</td>
<td>12.7 ± 7 h</td>
<td>ND</td>
<td>14.6 ± 31% viable, but included deliveries 25–37 h after LPS</td>
<td>[140]</td>
<td></td>
<td></td>
</tr>
<tr>
<td>N/A</td>
<td>CD-1</td>
<td>19–20</td>
<td>Overnight</td>
<td>Vaginal plug at 0.0 dpc</td>
<td>LPS serotype 0111:B4</td>
<td>IP 25 μg</td>
<td>16.5 dpc</td>
<td>Before 18.0 dpc</td>
<td>ND</td>
<td>28% w/o LPS; 0% with LPS</td>
<td>[84]</td>
<td></td>
<td></td>
</tr>
<tr>
<td>N/A</td>
<td>C57BL/6</td>
<td>19.5 ± 0.5</td>
<td>Overnight</td>
<td>Vaginal plug at 0.5 dpc</td>
<td>LPS serotype 0111:B4</td>
<td>IP 10 ng/ml</td>
<td>16.0 dpc</td>
<td>Before 18.0 dpc</td>
<td>ND</td>
<td>28% w/o LPS; 0% with LPS</td>
<td>[142]</td>
<td></td>
<td></td>
</tr>
<tr>
<td>N/A</td>
<td>C57BL/6</td>
<td>19.5 ± 0.5</td>
<td>ND</td>
<td>Vaginal plug at 0.5 dpc</td>
<td>LPS serotype 0111:B4</td>
<td>IP 10 μg</td>
<td>16.5 dpc</td>
<td>Before 18.0 dpc</td>
<td>ND</td>
<td>28% w/o LPS; 0% with LPS</td>
<td>[143]</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Inflammation</td>
<td>FVB/129</td>
<td>ND</td>
<td>C57BL6-129</td>
<td>Vaginal plug at 1.0 dpc</td>
<td>LPS serotype 0111:B4</td>
<td>IP 10 ng/ml</td>
<td>16.0 dpc</td>
<td>Before 18.0 dpc</td>
<td>ND</td>
<td>28% w/o LPS; 0% with LPS</td>
<td>[84]</td>
<td></td>
<td></td>
</tr>
<tr>
<td>N/A</td>
<td>C3H/HeN</td>
<td>20–21</td>
<td>Timed pregnant (supplier)</td>
<td>ND</td>
<td>Interleukin-1</td>
<td>SC 15–17 dpc</td>
<td>Within 24 h</td>
<td>20–22 dpc</td>
<td>ND</td>
<td>~85% viability; 60.9 ± 11.7% pup death by 1 week of age</td>
<td>[61]</td>
<td></td>
<td></td>
</tr>
<tr>
<td>N/A</td>
<td>C57BL/6</td>
<td>19.5 ± 0.5</td>
<td>Overnight</td>
<td>Vaginal plug at 0.5 dpc</td>
<td>High-mobility group box-1</td>
<td>IA 9 ng</td>
<td>14.5 dpc</td>
<td>17.35 dpc</td>
<td>19.5 ± 0.5 dpc</td>
<td>ND</td>
<td>[64]</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Type of model</td>
<td>Targeted mutation</td>
<td>Mouse strain</td>
<td>Expected gestational length (days)</td>
<td>Breeding method</td>
<td>Defined start of pregnancy</td>
<td>Stimulant</td>
<td>Treatment/ experimental manipulation</td>
<td>Route and concentration</td>
<td>Day of injection</td>
<td>Preterm delivery definition</td>
<td>Term delivery definition in paper</td>
<td>Pup survival</td>
<td>Reference</td>
</tr>
<tr>
<td>--------------------</td>
<td>-------------------</td>
<td>--------------</td>
<td>-----------------------------------</td>
<td>----------------</td>
<td>--------------------------</td>
<td>-----------</td>
<td>-------------------------------------</td>
<td>--------------------------</td>
<td>----------------</td>
<td>-------------------------------</td>
<td>--------------------------------</td>
<td>-------------</td>
<td>-----------</td>
</tr>
<tr>
<td>Cesarean</td>
<td>N/A</td>
<td>CD-1</td>
<td>20</td>
<td>Overnight</td>
<td>Vaginal plug at 1.0 dpc</td>
<td>Cesarean</td>
<td>Cesarean</td>
<td>NA</td>
<td>On 18 or 19 dpc</td>
<td>20 dpc</td>
<td>0% (18 dpc), 87.8% (19 dpc)</td>
<td>[65]</td>
<td></td>
</tr>
<tr>
<td>PPROM</td>
<td>N/A</td>
<td>C57BL/6</td>
<td>19.5 ± 0.5</td>
<td>Timed pregnant (supplier)</td>
<td>ND</td>
<td>Fetal fibronectin</td>
<td>Between fetal membranes and uterine lining (100-200 μg/ml)</td>
<td>NA</td>
<td>&lt;18.5 dpc</td>
<td>19 dpc</td>
<td>20%</td>
<td>[70]</td>
<td></td>
</tr>
<tr>
<td>Early progesterone withdrawal</td>
<td>N/A</td>
<td>C3H/HeN</td>
<td>19–20</td>
<td>Overnight</td>
<td>Vaginal plug at 0.0 dpc</td>
<td>NA</td>
<td>Mifepristone (RU486)</td>
<td>SC 50–250 μg</td>
<td>12–14 dpc</td>
<td>19–20 dpc</td>
<td>100%</td>
<td>[75]</td>
<td></td>
</tr>
<tr>
<td>Prostaglandins</td>
<td>N/A</td>
<td>C3H/HeN</td>
<td>19–20</td>
<td>Timed pregnant (supplier)</td>
<td>ND</td>
<td>Prostaglandin F2α</td>
<td>IP 20 μg</td>
<td>16 dpc</td>
<td>Within 24 h</td>
<td>&lt;18 dpc</td>
<td>ND</td>
<td>[82]</td>
<td></td>
</tr>
<tr>
<td>Uterine quiescence</td>
<td>N/A</td>
<td>CD-1</td>
<td>19</td>
<td>Timed pregnant (supplier)</td>
<td>ND</td>
<td>Tunicamycin</td>
<td>IP 0–1 mg/kg</td>
<td>15 dpc</td>
<td>18–32 h postinjection</td>
<td>19 dpc</td>
<td>Nonviable neonates at 16 and 17 dpc</td>
<td>[89]</td>
<td></td>
</tr>
<tr>
<td>Endocannabinoid signaling</td>
<td>CB1 knockout</td>
<td>C57BL/6J/129</td>
<td>20.1</td>
<td>Overnight</td>
<td>Vaginal plug at 1.0 dpc</td>
<td>NA</td>
<td>NA</td>
<td>Before ~19.5</td>
<td>~20.1 dpc</td>
<td>Yes</td>
<td>[99]</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Hyperhomocysteinemia</td>
<td>CBS knockout</td>
<td>C57BL/6J</td>
<td>20.0 ± 0.2</td>
<td>Overnight</td>
<td>Vaginal plug at 0.5 dpc</td>
<td>NA</td>
<td>NA</td>
<td>At 16.6 ± 0.1 dpc</td>
<td>20.0 ± 0.2 dpc</td>
<td>Yes</td>
<td>[102]</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
**Table 1. Continued**

<table>
<thead>
<tr>
<th>Type of model</th>
<th>Targeted mutation</th>
<th>Mouse strain</th>
<th>Expected gestational length (days)a</th>
<th>Breeding method</th>
<th>Defined start of pregnancyb</th>
<th>Treatment/ experimental manipulation</th>
<th>Routec and concentration</th>
<th>Day of injection</th>
<th>Preterm delivery definition</th>
<th>Term delivery definition in paper</th>
<th>Pup survival</th>
<th>Reference</th>
</tr>
</thead>
<tbody>
<tr>
<td>Environmental effects</td>
<td>N/A</td>
<td>C57BL/6</td>
<td>19.5 ± 0.5</td>
<td>Overnight</td>
<td>Vaginal plug at 0.5 dpc</td>
<td>2,3,7,8-tetrachlorodibenzo-p-dioxin (dioxin)</td>
<td>Mother was gavaged 10 μg/kg; no exposure as adult</td>
<td>In utero at 15.5 dpc, none as adult</td>
<td>24 h before term</td>
<td>20 dpc</td>
<td>Preterm</td>
<td>[105]</td>
</tr>
<tr>
<td>Other</td>
<td>N/A</td>
<td>BL6C3F1</td>
<td>20.3 ± 0.2</td>
<td>Two days</td>
<td>First day of pairing defined as 0.0 dpc</td>
<td>Cigarette smoke diluted 90%</td>
<td>Inhalation</td>
<td>2–18 dpc</td>
<td>At 19.6 ± 0.2 dpc</td>
<td>20.3 ± 0.2 dpc</td>
<td>Yes</td>
<td>[145]</td>
</tr>
<tr>
<td></td>
<td>N/A</td>
<td>CD-1</td>
<td>19–20</td>
<td>Overnight</td>
<td>Vaginal plug at 0 L-arginine analog Nω-nitro-L-arginine methyl ester (L-NAME)</td>
<td>Inhalation</td>
<td>15.5 dpc and 16 dpc</td>
<td>Before 18 dpc</td>
<td>18–19.5 dpc</td>
<td>Maternal cannibalism precluded evaluation</td>
<td>[107]</td>
<td></td>
</tr>
<tr>
<td></td>
<td>N/A</td>
<td>CD-1</td>
<td>19–20</td>
<td>Overnight</td>
<td>Vaginal plug at 0 Methylene Blue</td>
<td>Inhalation</td>
<td>15.5 dpc and 16 dpc</td>
<td>Before 18 dpc</td>
<td>18–19.5 dpc</td>
<td>Appeared viable but maternal cannibalism precluded evaluation</td>
<td>[108]</td>
<td></td>
</tr>
<tr>
<td></td>
<td>N/A</td>
<td>ICR (CD-1)</td>
<td>19–20</td>
<td>Overnight</td>
<td>Vaginal plug at 0.5 dpc</td>
<td>Surfactant protein (SP)-A</td>
<td>IA 3 μg in 50 μl per sac</td>
<td>15 dpc</td>
<td>ND</td>
<td>19 dpc</td>
<td>ND</td>
<td>[109]</td>
</tr>
<tr>
<td></td>
<td>N/A</td>
<td>BALBC</td>
<td>20.2 ± 0.1</td>
<td>Overnight</td>
<td>Vaginal plug at 0 Neuromedin B</td>
<td>Inhalation</td>
<td>18 dpc and 19 dpc at 1400 h</td>
<td>ND</td>
<td>ND</td>
<td>ND</td>
<td>[110]</td>
<td></td>
</tr>
<tr>
<td></td>
<td>N/A</td>
<td>C57Bl/6J</td>
<td>19.5 ± 0.5</td>
<td>ND</td>
<td>Vaginal plug at 1 AlcohO</td>
<td>Inhalation</td>
<td>17 dpc or 18 dpc</td>
<td>18.9 ± 0.1 dpc</td>
<td>20.1 ± 0.1 dpc</td>
<td>ND</td>
<td>[111]</td>
<td></td>
</tr>
</tbody>
</table>

---

*a As discussed by author or determined by [16]
*b dpc, days postcoital
*c IA, intraamniotic; IP, intraperitoneal; IU, intruterine; SC, subcutaneous
*d includes term deliveries
*NA, not applicable
*ND, not discussed
*LPS, Lipopolysaccharide
apoptosis. In another model, 75% of mice that were vaginally colonized with GBS on 16 dpc delivered preterm. However, 0% of mothers that were vaccinated with GBS before mating delivered preterm, and their pups had higher survival rates and lower levels of neonatal GBS infection than those from unvaccinated mothers [42].

Another bacterial genus that commonly infects the uterus and causes preterm birth in humans is Ureaplasma, a member of the Mycoplasmataceae family [43]. Additionally, Ureaplasma is the most frequently isolated bacterial pathogen in cases of chorioamnionitis [44]. One group reported that injecting a diacylated lipopeptide derived from Ureaplasma parvum into the uterus of pregnant mice on 15 dpc resulted in preterm delivery, although the day of delivery was not defined. This work revealed that Ureaplasma likely induced preterm birth by binding to TLR-2 and activating the NF-κB inflammatory cascade [45].

The pathogen Chlamydia trachomatis is the most prevalent sexually transmitted bacteria and is associated with preterm delivery [46]. Mice infected with 10^5–10^7 inclusion-forming units (IFU) of C. trachomatis delivered on 15.8–16.4 dpc, whereas those infected with 10^3–10^4 IFU delivered on 19.5–19.6 dpc, and those that received vehicle or no treatment delivered had a mean gestation length of 19.3 dpc [47]. Acute to severe inflammation and C. trachomatis inclusions were noted in the maternal uterine wall, endometrium, and fetal membranes but were absent in the amnion and fetal organs.

Urine tract infections, most commonly caused by E. coli [48], have long been known to be associated with increased risk for preterm birth in humans [49]. To model this etiology, mice were infected with E. coli via urethral catheterization into the urinary bladder on 7 dpc. Nearly 90% of those infected with bacteria expressing the Dr adhesin delivered between 11 and 18 dpc [50], whereas only 10% of those infected with E. coli not expressing this Dr adhesin delivered preterm. Escherichia coli expressing Dr adhesin were able to colonize the kidneys and spleen of the mothers and transfer through the placenta to the fetuses, causing reduced fetal weight and poor organ development.

Maternal infections distant from the uterus have also been implicated in preterm birth. For example, some data suggest that maternal periodontal disease increases the risk of preterm birth by sevenfold [51]. Periodontal pathogens are capable of entering the bloodstream and spreading throughout the body and have been detected in the amniotic fluid [52, 53]. Moreover, P. gingivalis antigens have been detected in the placental women with chorioamnionitis [54]. In a mouse model of periodontal infection, P. gingivalis was injected into the first molar chambers of female mice 6 weeks before mating. Infected mice delivered 2 days earlier and had higher circulating levels of the proinflammatory cytokines tumor necrosis factor-alpha, interleukin (IL)-17, IL-6, and IL-1B than noninfected mice. Additionally, the bacteria were found in the placenta, and the mothers showed features of PPROM and placental abruption [55].

Inflammation

Inflammation in the absence of overt infection is a common etiology of preterm birth. In fact, sterile intra-amniotic inflammation is associated with ~26% of all preterm deliveries and is more common in early than in late preterm deliveries [56, 57]. An important contributor to sterile intra-amniotic inflammation is the cytokine IL-1, which is expressed in the human decidua, promotes prostaglandin production, and is detected at high levels in the uterus of women who deliver preterm [58]. IL-1 stimulates preterm birth in rabbits and nonhuman primates [59, 60]. To model this in mice, researchers injected pregnant mice with IL-1 three times between 15 and 17 dpc, leading to delivery within 24 h [61]. Other important players in sterile intra-amniotic inflammation are danger signals, such as damage-associated molecular pattern molecules and alarmins, which, upon stimulation by cellular stress and necrosis, activate the innate immune system [62]. One such alarmin, high mobility group box 1 (HMGB1), is increased in women with intra-amniotic inflammation [63]. To model this etiology of preterm birth, researchers injected HMGB1 into the amniotic sacs of fetuses on 14.5 dpc; 57% of the injected mice delivered by 17.5 dpc, whereas all of the controls delivered at full term (19.5 dpc) [64].

Cesarean section

To benefit maternal or fetal health, preterm cesarean delivery may be performed after either medically indicated or spontaneous preterm labor. To investigate the effect of cesarean delivery on fetal development and mortality, researchers surgically removed mouse fetuses before the normal delivery date and found that pups of the strain CD-1 could only be resuscitated when delivered on 19 or 20 dpc (20 dpc was the normal delivery time for this strain in their colony) [65], indicating that mice cannot survive outside the uterus if birth occurs more than 1 day preterm.

Preterm premature rupture of membranes

In women, PPROM is a significant pregnancy complication. In this condition, the chorioamniotic membrane surrounding the fetus ruptures before 37 weeks of pregnancy, breaching the barrier between the extruterine and intruterine environment, allowing the amniotic fluid to leak out, and increasing the risk for infection and preterm birth. PPROM can be caused by infection, overdistension of the uterus and amniotic sac (such as in multiple pregnancies), trauma, or genetic disorders. For example, women with Ehlers-Danlos syndrome carry mutations in the genes encoding proteins involved in assembly of collagen and elastic fibers and are at increased risk of PPROM, cervical insufficiency, uterine rupture, and delivering an intrauterine growth-restricted fetus [66]. C3H mice with targeted mutations in genes encoding specific proteoglycans, such as biglycan and decorin, displayed an Ehlers-Danlos-like phenotype that included reduced litter size and intruterine growth restriction. Additionally, despite lacking an inflammatory response, these mice delivered before 18.0 dpc, with 43% delivering by 17.0 dpc, and none of the fetuses survived [67].

The extracellular matrix glycoprotein fetal fibronectin (fFN) is part of the amniotic membranes, and detection of fFN in cervical and vaginal fluid has been associated with an increased risk for spontaneous preterm birth. However, few patients with a positive fFN result will actually deliver early [10, 68, 69]. In mice, injection of fFN at 17.0 dpc causes preterm delivery within 12–36 h, likely via PPROM induced by activation of matrix metalloproteinases and cyclooxygenase-2 [70]. Likewise, injecting mice with thrombin at 17.0 dpc increased levels of matrix metalloproteinases and cyclooxygenase-2 and caused delivery of non-viable pups within 24 h [70–72].

Early progesterone withdrawal

A successful pregnancy requires uterine smooth muscle quiescence before parturition/labor. During gestation, progesterone is one of the predominant hormones produced by the placenta and is responsible for keeping the myometrium in a quiescent state. Progesterone levels remain high throughout human pregnancy, but women undergo a
“functional” progesterone withdrawal at the end of pregnancy. This reduction in progesterone action is mediated by alterations in the ratio of progesterone receptor A to progesterone receptor B [73], changes in cofactor expression, and/or local metabolism of progesterone, thereby allowing contractions to initiate and the cervix to ripen [74]. Consistent with this idea, the anti-progesterone and anti-glucocorticoid drug Mifepristone, also known as RU486, induces uterine contractions and cervical ripening. To model early progesterone withdrawal, investigators injected mice with RU486 on 12–14 dpc, resulting in delivery within 18 h in ~84% of C3H/HeN mice. Although this study reported that pups were born alive, postnatal pup survival was not discussed [75]. RU486-induced premature cervical ripening in Bl6/129SvEv mice was reported to be similar to term ripening and distinct from LPS-induced premature ripening in terms of gene expression, immune cell populations, and microstructural reorganization of collagen [76, 77]. In other reports, RU486 was suggested to promote cervical remodeling by activating the complement receptor C5a [36].

Prostaglandins
At the end of human pregnancy, levels of the prostaglandins PGE$_2$ and PGF$_{2\alpha}$ increase, bind to receptors on the uterus, and promote contractions. Clinically, PGE$_1$ (misoprostol) is used to induce both uterine contractions and cervical ripening (effacement or thinning). As an alternative to giving women exogenous prostaglandins, mechanical compression of the cervix promotes local release of endogenous prostaglandins [78, 79]. To model excess prostaglandin activity in mice, researchers created a C57BL/6-129SvJ mouse line with a hypomorphic mutation in hydroxyprostaglandin dehydrogenase (PGDH), which hydrolyzes prostaglandins. These mice had elevated levels of PGE$_2$ and PGF$_{2\alpha}$ and delivered approximately one-half day early [80]. Consistent with these earlier studies, co-administration of PGE$_2$ and a PGDH inhibitor on gestation day 15 induced birth within 12 to 48 h [81]. In another study, C3H/HeN inbred wild-type mice treated with 20 μg of PGF$_{2\alpha}$ on 16 dpc delivered 19.3 h postinjection, whereas vehicle-injected mice delivered 53.5 ± 13.6 h postinjection [82].

Uterine senescence
One hypothesis states that gestation length is governed by the timing of placental and decidual senescence, marked by a reduction in telomere length, and that parturition is initiated when these tissues become “old” [83]. Cellular aging is prompted by signaling through mammalian target of rapamycin complex 1 (mTORC1). The tumor suppressor p53 reduces mTORC1 signaling by activating AMP kinase, thereby inhibiting the aging process. To examine the relationship between uterine senescence and parturition, mice were generated lacking p53 specifically in the uterus. Once pregnant, these mice had decreased AMP kinase activation and increased mTORC1 signaling, resulting in early decidual senescence and increased incidence of preterm delivery (before 19 dpc) in some females [84–86]. Modeling gene–environment interactions, work in this model demonstrated that low-dose LPS injection further increased the incidence of preterm birth [87].

Uterine quiescence
The protease caspase-3 helps maintain quiescence by cleaving contractile proteins during gestation [88]. Condon and colleagues hypothesized that caspase-3 is maintained in an active state during pregnancy by the endoplasmic reticulum (ER) stress response and that its activity is reduced by the unfolded protein response at the end of pregnancy. In support of this model, injecting mice with tunicamycin, which induces excessive ER stress response, on 15 dpc caused early increases in levels of the contractile proteins connexin-43, alpha actin, and gamma actin, and resulted in dose-dependent early onset of labor beginning on 16 dpc. Conversely, co-administration of 4-phenylbutrate, an inhibitor of ER stress, prevented both the increase in contractile proteins and preterm birth [89].

Endocannabinoid signaling pathway
In human pregnancy, levels of the endocannabinoid anandamide are high in early gestation, decrease during mid-gestation, and spike at the onset of labor [90, 91]. Anandamide is thought to affect parturition timing by controlling secretion of corticotropin-releasing hormone (CRH) [92], which regulates the duration of pregnancy and onset of labor [93, 94]. Anandamide and another cannabinoid, 2-arachidonoylglycerol, signal through the G protein-coupled cannabinoid receptor CB1 [95–98]. Deletion of the CB1 gene caused pregnant mice to go into preterm labor, delivering about one-half day before term. In this model, preterm delivery was thought to occur because of early progesterone withdrawal and increased estrogen production during pregnancy. Additionally, signaling through CB1 may control the CRH/corticosterone endocrine axis, as loss of CB1 caused an early rise in CRH and high levels of corticosterone during pregnancy [99].

Hyperhomocysteinemia
In a case-control study of 651 women, elevated homocysteine in maternal blood (hyperhomocysteinemia) during pregnancy was associated with increased odds of preterm birth [100]. One cause of hyperhomocysteinemia is a mutation in the gene encoding cystathionine B-synthase (CBS), an enzyme in the trans-sulfuration pathway [101]. To test a possible mechanism linking hyperhomocysteinemia to preterm birth, mice were generated carrying a mutation in CBS. CBS$^{-/-}$ pregnant mice had increased blood levels of homocysteine, developed preterm uterine contractions, and delivered significantly earlier (16.6 dpc vs. 20.2 dpc). Further analysis of this model demonstrated that the contractions were caused by preterm expression of the oxytocin receptor and increased PGE$_2$ synthesis by the enzyme prostaglandin endoperoxide synthase 2 [102].

Environmental effects: cigarette smoking and dioxin exposure
Women who smoke cigarettes during pregnancy are at a higher risk of delivering preterm than nonsmokers [103]. To model this etiology, Ng and Zelikoff exposed mice to cigarette smoke via inhalation between 2 and 18 dpc. The mice exposed to cigarette smoke delivered at 19.6 dpc, whereas unexposed mice delivered at 20.3 dpc; the pups survived in both groups [104]. A major toxic component of cigarettes is 2,3,7,8-tetrachlorodibenzo-p-dioxin (dioxin), which is also a ubiquitous environmental contaminant, a by-product of the industrialized process, and an endocrine disruptor. Because animals and humans are most sensitive to environmental toxicant exposure during in utero development, Bruner-Tran and Osteen exposed pregnant mice to dioxin and then examined the effects on fertility and preterm birth in the next two generations [105]. They found that 36% of females in the F1 generation delivered preterm as adults. Moreover, 25% of the F2 generation (which were exposed as germ cells of the F1 mice in utero) delivered preterm. Furthermore, when F1 females were exposed to GBS, mouse parvovirus, or LPS, the rates...
of preterm birth increased to 83, 86, and 100%, respectively [105, 106]. This model suggests that toxicant exposure acts additively with other risk factors to cause preterm birth.

Other models of PTB
Additional mouse models of preterm birth working through mechanisms of action not discussed above include inhibition of nitric oxide synthesis by treating mice with N^G^-nitro-L-arginine methyl ester [107]; inhibition of soluble guanylate cyclase by treating mice with methylene blue [108]; exogenous surfactant protein-A, which initiates the NF-κB-signaling cascade in the uterus [109]; injection of neuromedin B, which acts through its receptor to induce labor onset via the RELA (NF-κB P65)/IL6-mediated pathway [110]; and alcohol-induced preterm birth, which is associated with elevated levels of uterine PGE and PGF_2α and increased expression of contraction-associated proteins and is prevented by pretreatment with the prostaglandin synthesis inhibitor aspirin [14, 111].

Defining preterm birth in mouse models
Given the large number of available mouse preterm birth models, standard definitions would allow researchers to appropriately compare results between studies and make meaningful inferences for human preterm birth. We argue that two related questions should be addressed when considering available and newly developed models: (1) Is the gestational length truly shortened, or does delivery occur within the normal range for the mouse strain? (2) Does the model deliver pups that are developmentally immature at delivery? Below, we draw on representative examples listed in Table 1 to highlight variations in experimental design that complicate our ability to evaluate and compare the current mouse models of preterm birth.

Strain-specific characteristics
Researchers have used several different strains of mice to generate models of preterm birth. The mouse strain is an important consideration given the findings of Murray et al. that gestational lengths can vary by as much as 41.7 h, or a full 1.72 days [16]. For example, the FVB/NJ, C57BL/6J, 129S1/SVIMJ, and A/J strains have average gestational lengths of 450.6, 462.4, 486.3, and 492.3 h, respectively, corresponding to between 18.8 and 20.5 days [16]. Clearly, the strain background has to be considered when determining whether a preterm birth model has shortened gestation.

Approaches for timed matings
Comparing gestational lengths between studies is complicated by variations in breeding protocols. For example, whereas most investigators breed mice overnight, some breed for undefined periods of time, and others obtain timed-mated animals from commercial suppliers. Mating strategies should be standardized given that interlitter variability in fetal body weights is greater when mice are bred continuously than when they are mated for 2 h or overnight [112]. Additionally, our field should standardize the definition of the start of gestation. Investigators record the time at which they see a copulation plug as 0.0, 0.5, or 1.0 dpc. This could result in up to a 24-h difference in timing of gestational length, perhaps leading a delivery to be scored as preterm when it is within the normal variation of delivery time for that mouse strain.

Monitoring the timing of parturition
Multiple methods have been used to monitor the timing of delivery. The onset of parturition is typically defined as the time of delivery of the first pup, which can be precisely determined by using a video camera with infrared lighting to record events in the dark. In contrast, strategies such as checking the dam multiple times during the day and recording the pup number may lead to inaccuracies because newly delivered pups can be hidden in the bedding or may be cannibalized if the dam considers the offspring to be abnormal. Furthermore, mice subjected to frequent disturbances in their cage or a nearby cage may enact a “predator response” defense mechanism that can alter their parturition behavior [113]. If an investigator checks the dam only on the expected morning of delivery, he or she may not realize that offspring were already delivered and thus may report that gestation was longer than it actually was.

Measures of development
Few studies provide comprehensive fetal outcome measurements of their preterm birth models [108]. Typically, studies report survival of offspring born preterm (Table 1), yet few provide details on the pups’ developmental status (immature or mature).

Proposed guidelines for defining preterm birth in mouse models
For all studies, investigators should be aware that specific animal facility characteristics, such as diets, bedding, water, animal husbandry, co-housing with other pregnant dams, environment (conventional vs. barrier systems), and noise pollution, could affect gestation length. Thus, instead of relying on published values, investigators should measure and report gestational length in wild-type, untreated mice in the same facility in which they will do their experiments. Additionally, we suggest the following guidelines in reporting studies of existing and novel mouse models of preterm birth.

Breeding and timing of gestational length
Because gestational length varies by mouse strain, it is extremely important to breed controls of the same genetic background when using transgenic models. We suggest two methods of breeding:

Timed breeding
One of the most accurate methods for estimating gestational length is to restrict the mating period [112]. Because hormonally receptive females usually mate within 1 h [114], pairing estrus-stage females with males for 2 to 4 h and then checking for the presence of a copulation plug allows for accurate assessment of gestational length. Alternatively, multiple breeding cages of unstaged females can be set up for a restricted time. The time at which the copulation plug is noted should be recorded as 0.0 dpc, and the following morning should be considered 0.5 dpc. We recommend caution in using timed-mated mice in preterm birth studies provided by a commercial supplier, as gestational length is likely to be affected by shipping, handling of the mice, potential quarantine, temperature changes, and alterations in light-dark cycles.

Overnight breeding
When mice cannot be bred for a restricted time period or less precision is acceptable, mice can be bred overnight. Place estrus-stage dams with stud males overnight, and check for the presence of a copulation plug before 8:00 am the next day. This method is
Figure 1. Skin permeability as a marker of maturity. In C57BL/6 mice, dye permeated mice at 17.0 dpc. By 18.0 dpc, dye was excluded on the dorsal side, but the pup remained blue on the ventral side. By 19 dpc, the skin was impermeable and faint blue stain was only noted on the ventral side. (Please see the online version for the color figure.)

Skin barrier function
The skin forms a permeability barrier that regulates body temperature, prevents excess water loss, and prevents invasion by harmful pathogens. In humans, the epithelium fully develops its barrier function by late gestation (~34 weeks) [118]. Therefore, infants born before 30 weeks’ gestation are at increased risk for infection and loss of temperature and fluid [119, 120]. The barrier develops when the outer layer of the epidermis forms the stratum corneum, which is composed of a tough insoluble cornified envelope that is “glued” together by a complex extracellular lipid matrix [121]. Barrier function develops similarly in mice late in gestation, beginning at 17 dpc and developing in a dorsal-to-ventral pattern until birth, when the barrier is fully formed. Thus, assessment of barrier function can indicate developmental stage of pups.

Methods to assess skin barrier maturation
Barrier function can be assessed by performing a whole-mount skin permeability assay as previously reported [122]. To perform this assay, dissect pups from the dams on the day of delivery, place them in a solution containing the blue dye 5-bromo-4-chloro-3-indolyl-β-D-galactopyranoside (X-gal), and gently nutate for 8 h to overnight at 37°C [122]. Wash samples twice with phosphate-buffered saline, fix overnight in 4% formaldehyde at 4°C, and store in phosphate-buffered saline at 4°C. Evaluate pups for blue dye penetration. Figure 1 shows examples of pups at different gestational stages subjected to this assay. For C57Bl6/J mice at 17 dpc, the skin barrier is immature and fetuses are uniformly blue. By 18 dpc, the skin on the dorsal side starts to cornify and becomes impermeable to the dye and is thus white, while the ventral side is still permeable and thus is blue. By late 18 to 19.0 dpc, the skin barrier has fully formed and the skin is impermeable to the dye, so the pup is almost completely white.

Skin maturation can also be assessed histologically [123]. To perform this assay, dissect pups from the dams on the day of delivery, place them in a solution containing the blue dye 5-bromo-4-chloro-3-indolyl-β-D-galactopyranoside (X-gal), and gently nutate for 8 h to overnight at 37°C [122]. Wash samples twice with phosphate-buffered saline, fix overnight in 4% formaldehyde at 4°C, and store in phosphate-buffered saline at 4°C. Evaluate pups for blue dye penetration. Figure 1 shows examples of pups at different gestational stages subjected to this assay. For C57Bl6/J mice at 17 dpc, the skin barrier is immature and fetuses are uniformly blue. By 18 dpc, the skin on the dorsal side starts to cornify and becomes impermeable to the dye and is thus white, while the ventral side is still permeable and thus is blue. By late 18 to 19.0 dpc, the skin barrier has fully formed and the skin is impermeable to the dye, so the pup is almost completely white.

Skin maturation can also be assessed histologically [123]. To perform this assay, fix fetuses in 10% formalin, dehydrate them through an ethanol series, embed them in paraffin, cut 8 μm sections, mount the sections on glass slides, and perform routine hematoxylin and eosin (H&E) staining. Examine the skin for markers of maturation including thickness, stratification of the epidermal and dermal papillary layers, and hair follicle density. As shown in Figure 2, skin samples from 17 dpc pups have thin epidermal and dermal
Figure 2. Skin histologic changes during gestation. In whole mount, the skin of 17 dpc CD-1 fetuses appeared more translucent (A) than that of 19 dpc fetuses (C). H&E-stained sections of dorsal skin from 17 dpc fetuses had thinner epidermal (E) and dermal papillary (DP) layers and contained fewer hair follicles (asterisks) than H&E-stained sections of skin from 19 dpc fetuses (B and D). (Please see the online version for the color figure.)

Figure 3. Lung morphometry as a marker of lung maturity. H&E stained lungs from 17 and 19 dpc CD-1 mouse fetuses (A, B). Lung morphometry measurements indicated that, compared to 17 dpc lungs, 19 dpc lungs contained more airspaces (C), had larger airspace volume density (airspace area divided by total lung area) (D), and had larger airspace diameter (E). However, airspace perimeter was similar in the two groups (F). n = 6 for both 17 and 19 dpc; * P-values, calculated by t-test; error bars represent SEM. (Please see the online version for the color figure.)

Lung maturity markers
Lung development proceeds through markedly similar steps in mammals [124, 125]. This process begins with branching morphogenesis, in which the embryonic tracheal lung bud reiteratively branches to form large and small airways [126]. Branching morphogenesis is complete by mid-gestation in humans and mice and is followed by a period of mesenchymal thinning and epithelial differentiation. Finally, the lungs become alveolarized, during which alveolar septation expands the gas exchange structures of the lung [127]. In humans, this process begins at 36 weeks’ gestation and continues into early childhood [128, 129]. In mice, alveolarization occurs entirely postnatally, beginning at postnatal day 4–5 and becoming fully mature by postnatal day 30. We describe two methods that can be used to assess the extent of lung mesenchymal thinning and epithelial differentiation as a marker of fetal maturity in mice [130].

Morphometric assessment of lung maturation
Morphometric assessment of lung airspaces reveals the degree of mesenchymal thinning that occurs after branching morphogenesis is complete and before alveolarization initiates. To evaluate lung morphology, dissect out fetal lungs, section them, H&E stain the sections, and view the lung sections at ×40 magnification (Figure 3A and B). Avoid fields containing large vessels or airways. Use computer-assisted morphometry (e.g. Image-Pro Plus software; Media Cybernetics) to count the number of airspaces and measure airspace diameter and airspace perimeter. Calculate airspace volume density by dividing the sum of the airspace area by the total area (Figure 3C–F). In our experience, the airspace perimeter is the least reliable measure of lung maturity because airspace shape becomes more variable as the mesenchyme thins [131].

Protein and mRNA markers of lung epithelial differentiation
Infants born prematurely, especially at <34 weeks’ gestation, have pulmonary complications due to lung immaturity, and those infants that survive are at increased risk for long-term adverse pulmonary outcomes such as asthma, reduced lung function, and chronic lung disease [2, 5]. These pulmonary deficits are due, in part, to insufficient lung surfactant, composed of lipids and proteins that are secreted by fully differentiated type 2 alveolar epithelial cells. Surfactant reduces surface tension, helps maintain normal lung volumes, and is essential for normal breathing [132]. The four major protein components of surfactant are surfactant proteins B and C (SP-B and SP-C), which interact with phospholipids to improve surfactant dispersion at the air/liquid interface and prevent alveolar collapse [130, 133], and surfactant proteins A and D (SP-A and SP-D), which act as part of the innate immune system by opsonizing bacteria for clearance by pulmonary macrophages.

In mice, SP-A is expressed in the fetal lung late in gestation, becoming detectable in the amniotic fluid by 17.0 dpc and maximally expressed by 19.0 dpc [109]. Fetal SP-A is a particularly interesting marker of gestational lung maturity because it appears to help initiate parturition. Thus, detection of SP-A mRNA or protein in fetal lung or amniotic fluid could be used as a marker for fetal maturity in mice [109, 134]. SP-B, which is clinically administered to premature babies to treat surfactant deficiency, can likewise be used as a fetal
Figure 4. Gene expression as a marker of lung maturation. RNA isolated from pups of the indicated gestational ages was reverse transcribed to produce cDNA (SuperScript VILO kit; Invitrogen), and multiplex quantitative PCR reactions were performed with a StepOnePlus PCR System (Applied Biosystems) using the following FAM-labeled TaqMan Gene Expression assays (Applied Biosystems): SP-B Mm00455679, ENac Mm00803386, Aqp5 Mm00437578, SP-C Mm00488144, and Nkx2.1 Mm00447558. The VIC-labeled housekeeping gene, 18S, was used as an internal control. Triplicate ∆∆CT values were generated for each sample. mRNA levels relative to dpc 17 mRNA were calculated by using the equation FC = 2^−∆∆CT. n = 4 for each timepoint; *P values, calculated by one-way ANOVA with Dunnett post hoc analysis, denote comparisons between indicated values and 17 dpc values; error bars represent SEM.

As shown in Figure 4A, SP-B mRNA increases in the fetal lung by up to 5-fold between 17 and 19 dpc and by up to 10-fold at postnatal day 1. SP-C, a transmembrane protein expressed exclusively in alveolar type 2 cells postnatally, can similarly be used as a marker of lung maturity (Figure 4B)[135].

Two other proteins that can be used as markers of lung development are the water channel Aquaporin 5, which is expressed in alveolar type 1 cells and is thought to facilitate fluid absorption in the perinatal lung [136], and the epithelial sodium ion channel (ENaC). Two of the three ENaC subunits increase sharply in the mouse fetal
lung at late gestation [137]. As seen in Figure 4C and D, mRNA expression of ENaC and Aquaporin 5 increase in late gestation and can be used as markers of fetal lung maturity [135]. In addition to the above markers, panels of 50 or more genes have been evaluated as markers of fetal lung maturity in mice [130]. However, due to differences in mouse strain, detection methods, and reagents (primary antibodies, PCR primers), some of these proteinsgenes may not be reproducible markers. For example, we found that NK2 Homeobox 1 (Nkx2.1), an epithelial transcription factor critical for embryonic lung morphogenesis, was expressed at similar levels in 17 dpc, 19 dpc, and postnatal day 1 lungs. Therefore, we recommend that investigators evaluate multiple lung maturation markers. In addition, absolute levels of each marker are not sufficient to assess lung maturity and should always be compared to levels in full-term pups of the appropriate genotype and strain.

Conclusion

Researchers have used several mouse models to test hypotheses regarding preterm birth. These include models of genetic, infectious, noninfectious (sterile) inflammatory, environmental toxins, and endocrine etiologies. However, comparing data between studies is challenging given the lack of uniform criteria for defining preterm birth and assessing pup maturity. A recent review by Manuel et al. encourages investigators to develop better mouse models that are more consistent with the human etiologies of preterm birth [138]. In this review, we recommend that our field adopt standardized experimental and reporting guidelines to define preterm birth and use fetal developmental markers to distinguish between premature and mature pups. In addition to the skin and lung markers proposed here, we welcome other easy-to-use developmental markers. By standardizing our methods and reporting, mice should become an even more valuable model with which to study the important problems of preterm birth and the resulting neonatal co-morbidities.

Acknowledgments

We thank Dr Deborah J. Frank and Jessica Chubiz for critical reading and editing. We also thank Dr Xiaofeng Ma for help with the images.

References


74. Condon JC, Jeysauria P, Faust JM, Wilson JW, Mendelson CR. A decline in the levels of progesterone receptor coactivators in the pregnant uterus at term may antagonize progesterone receptor function and contribute to the initiation of parturition. Proc Natl Acad Sci USA 2003; 100:9518–9523.


